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Abstract
Background. EORTC study 22033–26033 showed no difference in progression-free survival between high-risk low-
grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treat-
ment. Considering the potential long-term deleterious impact of RT on memory functioning, this study aims to 
determine whether TMZ is associated with less impaired memory functioning.
Methods. Using the Visual Verbal Learning Test (VVLT), memory functioning was evaluated at baseline and sub-
sequently every 6 months. Minimal compliance for statistical analyses was set at 60%. Conventional indices of 
memory performance (VVLT Immediate Recall, Total Recall, Learning Capacity, and Delayed Recall) were used as 
outcome measures. Using a mixed linear model, memory functioning was compared between treatment arms and 
over time.
Results. Neuropsychological assessment was performed in 98 patients (53 RT, 46 TMZ). At 12 months, compliance 
had dropped to 66%, restricting analyses to baseline, 6 months, and 12 months. At baseline, patients in either treat-
ment arm did not differ in memory functioning, sex, age, or educational level. Over time, patients in both arms 
showed improvement in Immediate Recall (P = 0.017) and total number of words recalled (Total Recall; P < 0.001, 
albeit with delayed improvement in RT patients (group by time; P = 0.011). Memory functioning was not associated 
with RT gross, clinical, or planned target volumes.
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Conclusion. In patients with high-risk low-grade glioma there is no indication that in the first year after treat-
ment, RT has a deleterious effect on memory function compared with TMZ chemotherapy.
Key Points
1.  In high-risk low-grade glioma patients, RT does not have a deleterious effect on 
memory function compared with TMZ chemotherapy at one year.
2.  When considering the first year after treatment, the choice for either RT or TMZ 
chemotherapy does not need to be based on its neurotoxic profile concerning 
memory function.
Low-grade gliomas (LGGs) (World Health Organization 
[WHO] grade II astrocytomas and oligodendrogliomas) are 
a heterogeneous group of primary brain tumors commonly 
occurring in the third and 4th decade of life. Known clinical 
negative prognostic factors include older age, astrocytic his-
tology, a tumor diameter of 6 cm or more, tumors crossing 
the midline, and persistence of neurologic symptoms al-
ready present prior to surgery. Mutations in the isocitrate 
dehydrogenase 1 (IDH1) or IDH2 gene are commonly seen in 
LGGs. If accompanied by codeletion of chromosomal arms 
1p and 19q, this is diagnostic for oligodendroglioma that 
has a more protracted natural history and better response to 
both chemotherapy and irradiation compared with IDH mu-
tant astrocytoma.1
Surgery, radiotherapy (RT), and chemotherapy all have a 
role in the management of LGG; however, the sequence and 
optimal timing remain a matter of debate. The highly variable 
natural course and often initially indolent history warrant spe-
cial consideration of potential late treatment-related toxicities.
Immediate surgery is generally required for patients pre-
senting with a large mass or extensive neurologic symp-
toms. Retrospective studies suggest a survival advantage 
for early and radical tumor resection.2 However, the role 
for immediate postoperative (adjuvant) RT in LGG is less 
clearly defined. In a large 1980s-initiated EORTC study,3 
314 LGG patients were randomized to immediate versus 
deferred RT. Although early RT allowed for delaying the 
time to tumor progression, there was no overall survival 
(OS) difference between treatment groups. In a more re-
cent Radiation Therapy Oncology Group study,4 251 high-
risk LGG patients received RT and were subsequently 
randomized to receive or not to receive up to 6 cycles of 
procarbazine/lomustine/vincristine (PCV). With long-term 
follow-up of over a decade, prolonged OS was observed in 
patients who received adjuvant PCV.5 The benefit appears to 
be confined to the subgroup of patients with IDH mutation. 
At 10 years, OS was 60% (95% CI: 51‒69) and 40% (95% CI: 
31‒49) in the RT + PCV group and RT only group, respec-
tively. Neurocognitive functioning using the Mini-Mental 
State Examination (MMSE) was assessed at baseline and 
at 1, 2, 3, and 5 years follow-up. Since most patients in both 
arms experienced a gain in MMSE scores over time, with 
no difference between arms, the authors conclude that the 
addition of PCV to RT improves progression-free survival 
without excessive neurocognitive decline over RT alone.6 
In EORTC 22033-26033, where high-risk LGG patients were 
randomized to treatment with either temozolomide (TMZ) 
or RT,7 there was no difference in health-related quality of 
life (HRQoL) and MMSE between treatment arms during 
the 36 months of follow-up.8
Considering the low sensitivity of the MMSE to de-
tect changes in specific neurocognitive domains and the 
finding of a multicenter study where neurocognitive dis-
ability in the memory domain was a prominent feature of 
irradiated LGG patients,9 EORTC 22033-26033 incorporated 
comprehensive neurocognitive testing with a special focus 
on memory functioning in dedicated centers. Because of 
the extensive literature suggesting that brain RT is asso-
ciated with white matter changes, neurocognitive deficits, 
and radiation necrosis,9–11 we hypothesized that TMZ che-
motherapy would be associated with a more favorable 
memory outcome over time. To discern whether RT af-
fected memory outcome, we calculated the associations 
between RT brain target volumes and memory functioning 
at follow-up in the RT patient group.
Materials and Methods
Study Design and Participants
The EORTC–National Cancer Institute of Canada—
Canadian Cancer Trials Group (NCIC CTG)–Trans Tasman 
Importance of the Study
This is the first face-to-face study comparing 
memory effects of RT versus TMZ chemotherapy 
in high-risk low-grade glioma patients. This study 
showed improvement over a 12-month period 
with no difference between treatment arms. 
Radiotherapy patients, however, had a delayed re-
covery in memory functioning, probably associated 
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Radiation Oncology Group (TROG)–Medical Research 
Council (MRC)–Clinical Trial Unit (CTU) intergroup study, 
EORTC 22033-26033, was a prospective, randomized, open-
label, phase III study among patients with histologically 
verified high-risk supratentorial diffuse (WHO grade II) 
LGG (astrocytoma and oligodendroglioma). The protocol 
compared primary postoperative treatment modalities, 
standard RT (28  × 1.8 Gy/d, 50.4 Gy) versus dose-dense 
chemotherapy (TMZ 75  mg/m2 21/28  days × 12 cycles, 
Temodal, MSD/Merck & Co). A total of 78 medical centers 
and hospitals in 19 countries participated in the trial, which 
has been reported in detail previously.7
In the 8 participating centers listed in the acknow-
ledgments, additional comprehensive prospective 
neurocognitive evaluation was performed. These investi-
gations are the basis of the current report.
The study was approved by the institutional review 
boards and ethics committees of all participating centers 
and the respective authorities. The trial was completed ac-
cording to the Declaration of Helsinki. All patients provided 
written informed consent.
In addition to LGG patients, normative data from a co-
hort of healthy controls were included in this study.
Procedures
Baseline evaluation (within 6 weeks before randomiza-
tion and before the start of treatment) included contrast-
enhanced MRI, a neurological evaluation (including 
HRQoL, overall neurocognitive functioning using the 
MMSE, comprehensive neurocognitive assessments, 
and assessment of seizure frequency if applicable), and 
complete blood counts and blood chemistry as well. RT 
volumes were defined based on T2 or fluid-attenuated in-
version recovery MRI.
Health-related quality of life and overall neurocognitive 
(MMSE) functioning have been reported elsewhere.8 
Comprehensive neurocognitive assessments were per-
formed in selected European centers with specific in-
terest in this outcome measure of treatment efficacy. To 
ensure optimal compliance and to ensure standardiza-
tion of testing by all personnel, guidelines and training 
for neurocognitive assessments were provided to 
participating centers.
Memory functioning was assessed using the Visual 
Verbal Learning Test (VVLT).12 This version of the Rey 
Auditory Verbal Learning Test is a neuropsychological tool 
that is used for assessing episodic memory by providing 
scores for evaluating different aspects of memory. Briefly, 
the VVLT consists of a list of 15 words, which are visually 
presented to the patient 5 times, and then the patient is im-
mediately asked to recall as many words as he/she remem-
bers. This procedure is repeated for consecutive trials 1 to 
5. After 20 minutes of interpolated testing, the patient is 
again asked to recall the words (delayed recall). Different 
indices of learning and memory capacity are derived from 
raw VVLT scores. These include VVLT Immediate Recall (the 
number of words recalled on trial 1), which reflects imme-
diate word span under memory overload conditions; VVLT 
Total Recall (the total number of words recalled by trial 
5 [ie, trial 1 + trial 2 + trial 3 + trial 4 + trial 5]), reflecting 
efficiency of the memory encoding process; VVLT Learning 
Capacity (the score of trial 5 recall minus the score of trial 
1 recall); and VVLT Delayed Recall (the total number of 
words recalled after 20 minutes), reflecting efficiency of the 
memory consolidation process. After baseline, follow-up 
assessments were performed every 12 weeks using alter-
native forms to control for test–retest effects.
Per protocol, data collection was continued until pro-
gression, death, loss to follow-up, or if the patient refused 
further participation. Since inclusion of patients with pro-
gression would complicate interpretation of RT versus 
TMZ effects on memory function, only patients who did 
not progress during the observation period were selected 
for this analysis. Time windows for eligible follow-up as-
sessment were set at 6 weeks before and 6 weeks after 
the scheduled follow-up assessment. Forms completed 
outside the eligible time windows or duplicates within a 
window were removed from the analysis.
Statistical Analyses
All statistical analyses were done by AJD with SPSS 
version 22.0 for Windows according to a prespecified 
statistical analysis plan with compliance cutoff set at 
60%. Descriptive statistics were used to characterize the 
study sample. Student’s t-tests for independent samples 
and chi-square tests were done to test for differences 
in sociodemographic and clinical characteristics be-
tween the patients who had RT and those who had TMZ. 
Memory performance at baseline in the patients who had 
RT compared with those who had TMZ was assessed with 
one-way ANOVA. A  mixed model analysis was used to 
assess differences in memory performance over time be-
tween the patients who had RT and those who had TMZ. 
The mixed model included time point, treatment (ie, RT 
versus TMZ), and their interaction as fixed variables and 
participants as a random variable. Significant interactions 
were interpreted by performing post-hoc analyses using 
Bonferroni corrections for multiple comparisons. Within 
the RT patient group, bivariate correlations (Spearman’s 
rho) for each combination of memory measures and 
gross target volume, clinical target volume, and planned 
target volume were calculated at successive follow-up 
time points.
To determine how LGG patients’ memory differed 
from the healthy population, patients were individually 
matched to healthy controls based on age, level of educa-
tion, and sex. A sample of 470 healthy controls was used 
in the matching process. Matching was done using fuzzy 
matching with exact matches for sex and educational level 
and 5-year variability for age. One-way ANOVA was exe-
cuted for baseline and follow-up measurements using 
treatment arm as the predictor and the raw scores on the 
VVLT as the dependent variable. Significant differences be-
tween the groups were assessed with post-hoc analyses 
using Bonferroni corrections to correct for multiple com-
parisons. Statistical significance was set as at a P-value of 
<0.05 (two-tailed). Follow-up assessments for this study are 
ongoing and are registered at EudraCT (European Union 
Drug Regulating Authorities Clinical Trials Database), 
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Role of the Funding Source
EORTC was the study sponsor and was responsible for 
overseeing the conduct and statistical analyses. The study 
was conducted as an intergroup study in collaboration with 
NCIC, CTG, TROG, MRC, and CTU. MSD/Merck & Co (for-
merly Schering-Plough) supported this study with an unre-
stricted educational grant to EORTC and by providing free 
TMZ for the study. The funders of the study had no role in 
study design, data collection, data analysis, data interpre-
tation, or writing of the report. The corresponding author 
(MK), JD, TG, RS, and BGB had full access to all the data 
and had the final responsibility to submit for publication.
Results
Between December 6, 2005 and December 21, 2012, 4 hun-
dred seventy-seven of 707 registered patients (67%) were 
randomly assigned to receive RT (n = 240) or TMZ (n = 237). 
Of this group, 98 patients (Table 1) from the 8 centers in 4 
countries listed in the Acknowledgments underwent neu-
ropsychological testing. No significant differences were 
found between the RT and TMZ groups in tumor, clinical, 
and sociodemographic characteristics. Before start of 
treatment at baseline, 52 patients scheduled for RT and 
46 patients scheduled for TMZ were included. At 6 months 
follow-up, the compliance had dropped to 38 patients for 
TMZ and 40 patients for RT. At 12  months follow-up the 
compliance had dropped to 34 patients for TMZ and 35 
patients for RT. At 18 months follow-up, the participation 
rate had dropped to only 54% of the original sample. For 
this reason, all analyses were performed up to 12 months 
follow-up. The primary study endpoints and quality of life 
analyses have previously been reported.7,8
Memory Performance at Baseline
At baseline, patients did not differ significantly between 
treatment arms on the major indices of memory func-
tioning (VVLT Immediate Recall [P  =  0.532], VVLT Total 
Recall [P = 0.504], VVLT Learning Capacity [P = 0.728], and 
VVLT Delayed Recall [P = 0.900]).
Memory Performance Over Time
Figure 1A shows the VVLT Immediate Recall scores at the 
various time points for the 2 patient groups. Mixed linear 
model analysis showed no statistically significant interac-
tion effect of treatment over time at the group level on VVLT 
Immediate Recall, F(2,150) = 2.82, P = 0.063, indicating that 
immediate word span under memory overload conditions 
was not disproportionally affected by treatment with ei-
ther RT or TMZ. Over time, there was a significant improve-
ment in memory function—main effect of time on VVLT 
Immediate Recall F(2,150) = 4.19, P = 0.017—independently 
of treatment arm (P = 0.172).
Figure  1B shows the VVLT Total Recall scores by time 
point for the 2 treatment groups. Similar to the perfor-
mance on trial 1 of the VVLT, analyses also showed a 
statistically significant main effect of time for the VVLT 
Total Recall scores F(2,144)  =  10.5, P  <  0.001, indicating 
that patients were able to recall increasingly more items 
over the 5 trials during the 12  months follow-up period. 
There was no main effect of treatment (P = 0.583). There 
was a statistically significant group by time interaction 
effect, F(2,144) = 4.68, P  = 0.011. Post-hoc analyses using 
Bonferroni corrections to control for multiple comparisons 
detected no statistically significant differences between 
treatment groups at baseline (P  =  0.506), at 6  months 
(P = 0.146) or at 12 months follow-up (P = 0.515). In the TMZ 
patient group the VVLT Total Recall score was significantly 
lower at baseline compared with 6 months (P = 0.018) or to 
12 months (P < 0.001). No significant improvement in VVLT 
Total Recall score between 6 and 12 months (P = 0.311) was 
seen. VVLT Total Recall score in the RT group at baseline did 
not significantly differ from that at 6 months (P = 0.436) or 
at 12 months (P = 0.188). At 12 months the VVLT Total Recall 
score in the RT group was significantly higher when com-
pared with 6 months (P = 0.005). Repeated measures anal-
ysis showed no effect of treatment over time on learning 
capacity, F(2,148) = 1.278, P = 0.282 (Figure 1C). There were 
no main effects of time (P = 0.367) or treatment (P = 0.887).
In line with the findings for learning capacity, re-
peated measures analysis showed no effect of treat-
ment over time on VVLT Delayed Recall, F(2,148) = 2.695, 
P = 0.071(Figure 1D), no main effects of time (P = 0.057) or 
treatment (P = 0.294).
In the irradiated patients there was no statistically signif-
icant association between RT gross target volume, clinical 
target volume, and planned target volume and memory out-
come at 6 and 12 months follow-up (Tables 2 and 3). At base-
line there were also no statistically significant associations 
between gross tumor volume and memory outcomes.
Comparison with Healthy Controls
To have an additional anchor of memory performance, 
the treatment groups were compared with healthy con-
trols using one-way ANOVAs at baseline (see Table  4). 
The number of words recalled at trial 1 (VVLT Immediate 
Recall) differed significantly between the 3 groups 
(P < 0.001). Bonferroni post-hoc tests discerned that both 
the TMZ group (P  =  0.008) and the RT group (P  =  0.003) 
significantly differed from the control group at baseline; 
patients recalled more words at baseline compared with 
their matched healthy controls, possibly because of mo-
tivational factors. The number of words learned between 
trials 1 and 5 (VVLT Learning Capacity) differed signifi-
cantly between the 3 groups (P < 0.001). Bonferroni post-
hoc tests showed that both the TMZ group (P < 0.001) and 
the RT group (P  <  0.001) significantly differed from the 
control group of healthy subjects at baseline, specifically, 
patients learned less words between trials 1 and 5. These 
differences are indicative of relatively mild impairment 
and are unlikely to have a major impact in the everyday 
life of patients. There was, however, no significant differ-
ence between the groups in the total number of words re-
called from trial 1 through 5 (VVLT Total Recall) and recall of 
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Table 1. Patient characteristics 
Radiotherapy (n = 52) Temozolomide (n = 46) P*
Age, y 43 (sd = 10) 44 (sd = 11) 0.664
 <40 22 (42.3%) 18 (39.1%) 0.749
 ≥40 30 (57.7%) 28 (60.9%)  
Sex   0.484
 Male 19 (36.5%) 20 (43.5%)  
 Female 33 (63.5%) 26 (56.5%)  
Years of education 13 (sd = 4) 14 (sd = 4) 0.172
WHO performance status   0.549
 0 37 (71.2%) 31 (67.4%)  
 I 14 (26.9%) 15 (32.6%)  
 II 1 (1.9%) 0 (0%)  
Initial resection status (by investigator)   0.492
 Biopsy 25 (48%) 22 (48%)  
 Partial removal 20 (39%) 14 (30%)  
 Total removal 7 (14%) 10 (22%)  
Tumor characteristics    
 Tumor involving midline   0.603
  No 39 (75%) 35 (76%)  
  Midline shift 6 (12%) 6 (13%)  
  Midline infiltration 5 (10%) 5 (11%)  
  Both 2 (4%) 0 (0%)  
 Hemisphere   0.269
Left 29 (56%) 21 (46%)  
Right 20 (38%) 18 (39%)  
Both 3 (6%) 7 (15%)  
 Lobe   0.364
Frontal 17 (33%) 23 (50%)  
Occipital 1 (2%) 0 (0%)  
Parietal 2 (4%) 2 (4%)  
Temporal 13 (25%) 5 (11%)  
Multifocal 16 (31%) 14 (30%)  
Other 3 (6%) 2 (4%)  
WHO grade II histology   0.966
  Astrocytoma 20 (39%) 17 (37%)  
  Oligoastrocytoma** 13 (25%) 11 (24%)  
  Oligodendroastrocytoma 19 (37%) 18 (39%)  
Molecular markers    
 IDH1 or IDH2 mutation status   0.294
  IDH1 or IDH2 mutated 41 (79%) 34 (74%)  
  IDH wt 7 (14%) 4 (9%)  
  Undetermined 4 (8%) 8 (17%)  
 1p/19q status   0.926
  1p/19q codeleted 14 (27%) 11 (24%)  
  1p/19q non-codeleted 25 (48%) 25 (54%)  
  Undetermined 11 (21%) 8 (17%)  
  Missing 2 (4%) 2 (4%)  
Medication use    
 Corticosteroids 6 (12%) 0 (0%) *
 Anti-epileptics 47 (90%) 45 (98%) *
sd = standard deviation. *Chi-square tests cannot be calculated due to cells with less than the expected count of 5 cases. **Oligoastrocytomas 
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Discussion
This study aimed at determining whether there is a dif-
ference in treatment-associated memory functioning 
between RT and TMZ. Based on our prior observations, 
our hypothesis was that irradiation may negatively affect 
memory functioning, while chemotherapy would be de-
void of a detrimental neurological effect.9 However, over 
the 12-month observation period we were unable to de-
tect any significant difference in memory functioning be-
tween these treatment arms. This is in agreement with 
other studies demonstrating that cognitive decline might 
not be present 4 years after RT, and that it might take at 
least 5 years for cognitive decline to manifest itself after 
RT.13,14
Over time, patients in both arms showed improvement 
in immediate recall and the total number of words patients 
recalled by trial 5. Yet it remains unclear whether in LGG 
patients these gains in memory encoding efficiency also 
translate to improvements in instrumental activities of 
daily living (eg, telephone communication, financial man-
agement), as has been shown to be the case among HIV-
infected adults.15
Concerning the total number of words patients recalled, 
it is interesting to note that irradiated patients needed 
more time to benefit from repeated presentation of in-
formation than patients using TMZ. This suggests an early 
but transient side effect of RT on memory: detailed ana-
lyses demonstrated that this effect results from delayed 
improvement in memory performance in RT patients be-
tween the baseline and 6 month evaluation in comparison 
to patients treated with TMZ. This finding is in line with 
studies among patients receiving whole-brain RT, where 
neurocognitive deterioration may be present as early as 
3–4  months posttreatment.16,17 Interestingly, in these pa-
tients, memory function was preferentially affected as 
well.18,19
Considering the radiosensitivity of the hippocampus 
and its hypothesized clinical implications,20 it would be 
tempting to postulate that the delayed memory effect in 
the RT patients would be due to reduced neurogenesis 
in the subgranular zone of the hippocampus and the 
subventricular zone of the lateral ventricles.21 Based on 
a study among adult patients with benign or low-grade 
brain tumors,22 Gondi suggested that sparing of the 
hippocampus or rather the hippocampal neural stem-
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Fig. 1 Scoring profiles for the 2 treatment arms on the Visual Verbal Learning Test over time. (A) Immediate recall, the number of items recalled 
in trial 1. (B) Total recall, the total number of items recalled over trials 1–5. (C) Learning, the number of additional items learned between trials 1 
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might prevent long-term memory impairment. In a 
previous study we found effects of conventional, non-
hippocampal-sparing RT specifically on memory func-
tioning 6 years after initial diagnosis.9 However, when a 
subsample was again tested at a mean of 12 years after 
first diagnosis,23 we found a progressive decline in at-
tentional, but not in memory, functioning in irradiated 
patients. In our opinion, this lack of a memory decline 
suggests that other mechanisms, like time-dependent 
reorganization of the neuronal circuitry underlying long-
term memory storage, might also play a role in the long-
term outcome.24,25
A number of dosimetry studies recently evaluated the 
radiosensitivity of cortical regions important for higher-
order cognition, like memory, executive function, and 
attention,26 and found entorhinal (memory) and inferior 
  
Table 2. Spearman’s rho correlation coefficients at 6 months follow-up
Gross Tumor Volume Clinical Target Volume Planning Target Volume
Immediate 
Recall
Spearman’s rho 0.185 0.141 0.079
sig. (2-tailed) 0.287 0.399 0.633
N 35 38 39
Total Recall Spearman’s rho −0.019 −0.007 −0.067
sig. (2-tailed) 0.912 0.967 0.685
N 35 38 39
Learning Spearman’s rho −0.208 −0.254 −0.284
sig. (2-tailed) 0.230 0.123 0.079
N 35 38 39
Delayed Recall Spearman’s rho −0.073 −0.103 −0.190
sig. (2-tailed) 0.680 0.546 0.254
N 34 37 38
  
  
Table 3. Spearman’s rho correlation coefficients at 12 months follow-up
Gross Tumor Volume Clinical Target Volume Planning Target Volume
Immediate 
Recall
Spearman’s rho −0.018 −0.013 −0.007
sig. (2-tailed) 0.926 0.943 0.968
N 30 33 34
Total Recall Spearman’s rho −0.188 −0.113 −0.168
sig. (2-tailed) 0.320 0.530 0.342
N 30 33 34
Learning Spearman’s rho 0.036 −0.038 −0.095
sig. (2-tailed) 0.850 0.834 0.591
N 30 33 34
Delayed Recall Spearman’s rho −0.194 −0.165 −0.249
sig. (2-tailed) 0.305 0.358 0.155
N 30 33 34
  
  
Table 4. Baseline comparison between treatment groups and healthy controls
TMZ RT Healthy Controls P
VVLT Immediate Recall (trial 1) 6.2 (0.3) 6.3 (0.3) 5.2 (0.2) <0.001
VVLT total recall (trial 1 to 5) 46.5 (1.5) 46.9 (1.3) 45.7 (1.0) 0.754
VVLT Learning Capacity (trials 5-1) 4.8 (0.3) 5.0 (0.3) 6.4 (0.2) <0.001
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parietal (attention/memory) areas of the cerebral cortex to 
be most vulnerable to radiation-related atrophy. Cortical 
thinning increased with the total dose, but interestingly 
varied depending on the cortical location.26 Our earlier23 
findings that LGG patients who received RT in the long 
run have deficits in several higher-order domains of 
neurocognitive functioning (ie, attentional, executive, 
and information processing) support the notion that the 
effects of RT likely are not limited to the hippocampus 
and the memory domain. In this light, a cortex-sparing 
approach based on the finding that RT doses above 28.6 
Gy resulted in a greater than 20% probability of cortical 
atrophy27 is promising but needs to be confirmed by as-
sessing their survival and clinical benefit in large num-
bers of patients. Evidently, several other factors may 
explain long-term neurocognitive impairment observed 
following brain RT.23
Despite the large number of papers addressing the effects 
of RT, the psychometric quality of most papers is limited. 
Unequivocally interpretable information on the potential ef-
fects of TMZ on neurocognitive functioning in LGG patients is 
lacking. Toxicity of TMZ is in general acceptable at commonly 
used doses,28 although elderly patients potentially run higher 
risks of developing neurocognitive deficits during the con-
comitant course of the Stupp regimen.29
Our study is the first prospective randomized, 
multicenter, head-to-head comparison of the effect of 
these 2 treatment modalities in LGG patients. Although 
only a subgroup of patients in selected centers could 
undergo repeat detailed neurocognitive assessments, 
our dataset is on a homogeneous group of patients 
with histologically verified and centrally reviewed dif-
fuse LGG. Other strengths were the prospective study 
design with prespecified time points for measurements 
of neurocognitive functioning. However, our study 
is also subject to the limitations of brain tumor trials 
incorporating assessments of neurocognitive func-
tioning, the most important being missing data due to in-
sufficient compliance. Common reasons for missing data 
usually are administrative failure, patient refusal, and 
poor health status of the patient. Another limitation is that 
only memory functioning has been studied. Although the 
strongest impact of RT was expected on memory func-
tioning because of hippocampal damage, it would be 
interesting to investigate the effect of treatment type on 
other cognitive domains such as executive functioning 
and attention.
In conclusion, in the first year, the effect of TMZ chemo-
therapy or RT on memory functioning did not differ in pa-
tients with high-risk LGG.
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